Assessment of ATRX expression in patients with myelodysplastic syndromes treated with decitabine.
Steensma
David P
DP
Porcher
Julie C
JC
Litzow
Mark R
MR
Hogan
William J
WJ
Arora
Sujata
S
Van Laar
Emily S
ES
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D001374:Azacitidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D050677:Core Binding Factor Alpha 3 Subunit / Q000235:genetics; D020732:Cytogenetic Analysis; D004265:DNA Helicases / Q000235:genetics*; D000077209:Decitabine; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D009687:Nuclear Proteins / Q000235:genetics*; D011379:Prognosis; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D012334:RNA, Neoplasm / Q000235:genetics / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D000075924:X-linked Nuclear Protein
D000964:Antimetabolites, Antineoplastic; D050677:Core Binding Factor Alpha 3 Subunit; D009687:Nuclear Proteins; D012333:RNA, Messenger; D012334:RNA, Neoplasm; C493729:Runx3 protein, human; D000077209:Decitabine; D004265:DNA Helicases; C092332:ATRX protein, human; D000075924:X-linked Nuclear Protein; D001374:Azacitidine